The role of the mineralocorticoid receptor in the vasculature

Journal of Endocrinology

Volumn 234, Issue 1, 2017, Pages T67-T82

  DuPont, Jennifer J ^a   Jaffe, Iris Z ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Cardiovascular; Hormone receptors; Renin angiotensin system; Vasculature

Indexed keywords

MINERALOCORTICOID RECEPTOR; MINERALOCORTICOID ANTAGONIST;

ACUTE KIDNEY FAILURE; AGING; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; ENDOTHELIUM CELL; GENE CONTROL; GENETIC ENGINEERING AND GENE TECHNOLOGY; HEART INFARCTION; HUMAN; HYPERTENSION; IN VIVO STUDY; META ANALYSIS (TOPIC); MOLECULAR PATHOLOGY; NONHUMAN; OBESITY; OCULAR BLOOD VESSEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CARDIOVASCULAR FUNCTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; GENE EXPRESSION REGULATION; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID;

EID: 85023205146     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-17-0009     Document Type: Review

References (114)

1. Alzamora R, Michea L & Marusic ET. 2000. Role of 11beta-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension 35:1099-104. (doi:10.1161/01.HYP.35.5.1099)
2. Amador CA, Bertocchio JP, Andre-Gregoire G, Placier S, Duong Van Huyen JP, EI Moghrabi S, Berger S, Warnock DG, Chatziantoniou C, Jaffe IZ, et al. 2016. Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration. Kidney International 89:354-362. (doi:10.1038/ki.2015.312)
3. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE & Evans RM. 1987. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268-275. (doi:10.1126/science.3037703)
4. Ayuzawa N, Nagase M, Ueda K, Nishimoto M, Kawarazaki W, Marumo T, Aiba A, Sakurai T, Shindo T & Fujita T. 2016. Rac1-mediated activation of mineralocorticoid receptor in pressure overloadinduced cardiac injury. Hypertension 67:99-106. (doi:10.1161/HYPERTENSIONAHA.115.06054)
5. Barrera-Chimal J, Prince S, Fadel F, El Moghrabi S, Warnock DG, Kolkhof P & Jaisser F. 2016. Sulfenic acidmodification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia. Journal of the American Society of Nephrology 27:398-404. (doi:10.1681/ASN.2014121216)
6. Barrera-Chimal J, André-Grégoire G, Nguyen Dinh Cat A, Lechner SM, Cau J, Prince S, Kolkhof P, Loirand G, Sauzeau V, Hauet T, et al. 2017. Benefit of mineralocorticoid receptor antagonism in AKI: Role of vascular smooth muscle Rac1. Journal of the American Society of Nephrology. pii: ASN.2016040477. (doi: 10.1681/ASN.2016040477)
7. Barrett Mueller K, Lu Q, Mohammad NN, Luu V, McCurley A, Williams GH, Adler GK, Karas RH & Jaffe IZ. 2014. Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function. Endocrinology 155:4461-4472. (doi:10.1210/en.2014-1270)
8. Barrett Mueller K, Bender SB, Hong K, Yang Y, Aronovitz M, Jaisser F, Hill MA & Jaffe IZ. 2015. Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure. Hypertension 66:988-997. (doi:10.1161/HYPERTENSIONAHA.115.06172)
9. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, et al. 2007. Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine 357:2109-2122. (doi:10.1056/NEJMoa0706628)
10. Bender SB, DeMarco VG, Padilla J, Jenkins NT, Habibi J, Garro M, Pulakat L, Aroor AR, Jaffe IZ & Sowers JR. 2015. Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction. Hypertension 65:1082-1088. (doi:10.1161/HYPERTENSIONAHA.114.04912)
11. Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH & Garg R. 2007. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. Journal of Clinical Endocrinology & Metabolism 92:4472-4475. (doi:10.1210/jc.2007-1088)
12. Bonauer A, Boon RA & Dimmeler S. 2010. Vascular microRNAs. Current Drug Targets 11:943-949. (doi:10.2174/138945010791591313)
13. Boon RA, Seeger T, Heydt S, Fischer A, Hergenreider E, Horrevoets AJ, Vinciguerra M, Rosenthal N, Sciacca S, Pilato M, et al. 2011. MicroRNA-29b in aortic dilation: implications for aneurysm formation. Circulation Research 109:1115-1119. (doi:10.1161/CIRCRESAHA.111.255737)
14. Brem AS, Bina RB, King TC & Morris DJ. 1998. Localization of 2 11beta-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension 31:459-462. (doi:10.1161/01.HYP.31.1.459)
15. Bretschneider M, Busch B, Mueller D, Nolze A, Schreier B, Gekle M & Grossmann C. 2016. Activated mineralocorticoid receptor regulates micro-RNA-29b in vascular smooth muscle cells. FASEB Journal 30:1610-1622. (doi:10.1096/fj.15-271254)
16. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME & Jaffe IZ. 2008. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circulation Research 102:1359-1367. (doi:10.1161/CIRCRESAHA.108.174235)
17. Ceolotto G, Papparella I, Bortoluzzi A, Strapazzon G, Ragazzo F, Bratti P, Fabricio AS, Squarcina E, Gion M, Palatini P, et al. 2011. Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. American Journal of Hypertension 24:241-246. (doi:10.1038/ajh.2010.211)
18. Chen L, Ding ML, Wu F, He W, Li J, Zhang XY, Xie WL, Duan SZ, Xia WH & Tao J. 2016. Impaired endothelial repair capacity of early endothelial progenitor cells in hypertensive patients with primary hyperaldosteronemia: role of 5, 6, 7, 8-tetrahydrobiopterin oxidation and endothelial nitric oxide synthase uncoupling. Hypertension 67:430-439. (doi:10.1161/HYPERTENSIONAHA.115.06597)
19. Christy C, Hadoke PW, Paterson JM, Mullins JJ, Seckl JR & Walker BR. 2003. 11beta-hydroxysti dehydrogenase type 2 in mouse aorta: localization and influence on response to glucocorticoids. Hypertension 42:580-587. (doi:10.1161/01.HYP.0000088855.06598.5B)
20. Conn JW, Knopf RF & Nesbit RM. 1964. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. American Journal of Surgery 107:159-172. (doi:10.1016/0002-9610(64)90252-1)
21. Davel AP, Anwar IJ & Jaffe IZ. 2017. The endothelial mineralocorticoid receptor: mediator of the switch from vascular health to disease. Current Opinion in Nephrology and Hypertension 26:97-104. (doi:10.1097/MNH.0000000000000306)
22. Deliyanti D, Miller AG, Tan G, Binger KJ, Samson AL & Wilkinson-Berka JL. 2012. Neovascularization is attenuated with aldosterone synthase inhibition in rats with retinopathy. Hypertension 59:607-613. (doi:10.1161/HYPERTENSIONAHA.111.188136)
23. Deliyanti D, Armani R, Casely D, Figgett WA, Agrotis A & Wilkinson-Berka JL. 2014. Retinal vasculopathy is reduced by dietary salt restriction: involvement of Glia, ENaCα, and the renin-angiotensinaldosterone system. Arteriosclerosis, Thrombosis, and Vascular Biology 34:2033-2041. (doi:10.1161/ATVBAHA.114.303792)
24. Dinh QN, Young MJ, Evans MA, Drummond GR, Sobey CG & Chrissobolis S. 2016. Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor. Brain Research 1637:146-153. (doi:10.1016/j.brainres.2016.02.034)
25. Dorrance AM, Osborn HL, Grekin R & Webb RC. 2001. Spironolactone reduces cerebralinfarct size and EGF-receptor mRNA in strokeprone rats. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 281:R944-R950
26. Dorrance AM, Rupp NC & Nogueira EF. 2006. Mineralocorticoid receptor activation causes cerebral vessel remodeling and exacerbates the damage caused by cerebral ischemia. Hypertension 47:590-595. (doi:10.1161/01.HYP.0000196945.73586.0d)
27. Drüppel V, Kusche-Vihrog K, Grossmann C, Gekle M, Kasprzak B, Brand E, Pavenstadt H, Oberleithner H & Kliche K. 2013. Long-term application of the aldosterone antagonist spironolactone prevents stiff endothelial cell syndrome. FASEB Journal 27:3652-3659. (doi:10.1096/fj.13-228312)
28. DuPont JJ, McCurley A, Davel AP, McCarthy J, Bender SB, Hong K, Yoo JK, Aronovitz M, Baur WE, Christou DD, et al. 2016. Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging. Journal of Clinical Investigation Insight 1:e88942. (doi:10.1172/jci.insight.88942)
29. Fiebeler A, Schmidt F, Müller DN, Park J, Dechend R, Bieringer M, Shagdarsuren E, Breu V, Haller H & Luft FC. 2001. Mineralocorticoid receptor affects AP-1 and nuclear factor-kB activation in angiotensin II-induced cardiac injury Hypertension 37 787-793. (doi:10.1161/01. HYP.37.2.787)
30. Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schutz G, Frantz S, Ertl G & Bauersachs J. 2011. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123:400-408. (doi:10.1161/CIRCULATIONAHA.110.983023)
31. Fujimura N, Noma K, Hata T, Soga J, Hidaka T, Idei N, Fujii Y, Mikami S, Maruhashi T, Iwamoto Y, et al. 2012. ROCK Study Group: Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. Clinical Pharmacology & Therapeutics 91:289-297. (doi:10.1038/clpt.2011.227)
32. Funder JW, Pearce PT, Smith R & Smith AI. 1988. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583-585. (doi:10.1126/science.2845584)
33. Galigniana MD. 1998. Native rat kidney mineralocorticoid receptor is a phosphoprotein whose transformation to a DNA-binding form is induced by phosphatases. Biochem Journal 333:(Part 3) 555-563. (doi:10.1042/bj3330555)
34. Galmiche G, Pizard A, Gueret A, El Moghrabi S, Ouvrard-Pascaud A, Berger S, Challande P, Jaffe IZ, Labat C, Lacolley P, et al. 2014. Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension 63:520-526. (doi:10.1161/HYPERTENSIONAHA.113.01967)
35. Gemenetzi M, De Salvo G & Lotery AJ. 2010. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (London) 24:1743-1756. (doi:10.1038/eye.2010.130)
36. Ghadiali Q, Jung JJ, Yu S, Patel SN & Yannuzzi LA. 2016. Central serous chorioretinopathy treated with mineralocorticoidantagonists: A one-year pilot study. Retina 36:611-618. (doi:10.1097/IAE.0000000000000748)
37. Gueret A, Harouki N, Favre J, Galmiche G, Nicol L, Henry JP, Besnier M, Thuillez C, Richard V, Kolkhof P, et al. 2016. Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction. Hypertension 67:717-723. (doi:10.1161/HYPERTENSIONAHA.115.06709)
38. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R & Yamamoto H. 1994. Vascular aldosterone biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. Journal of Biological Chemistry 269:24316-24320
39. Huby AC, Antonova G, Groenendyk J, Groenendyk J, Gomez-Sanchez CE, Bollag WB, Filosa JA & Belin de Chantemele EJ. 2015. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 132:2134-2145. (doi:10.1161/CIRCULATIONAHA.115.018226)
40. Huby AC, Otvos L & Belin de Chantemèle EJ. 2016. Leptin induces hypertension and endothelial dysfunction via aldosterone-dependent mechanisms in obese female mice. Hypertension 67:1020-1028. (doi:10.1161/HYPERTENSIONAHA.115.06642)
41. Hwang MH, Yoo JK, Luttrell M, Kim HK, Meade TH, English M, Segal MS & Christou DD. 2013. Mineralocorticoid receptors modulate vascular endothelial function in human obesity. Clinical Science 125:513-520. (doi:10.1042/CS20130200)
42. Jaffe IZ & Mendelsohn ME. 2005. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circulation Research 96:643-650. (doi:10.1161/01.RES.0000159937.05502.d1)
43. Jaffe IZ, Tintut Y, Newfell BG, Demer LL & Mendelsohn ME. 2007. Mineralocorticoid receptor activation promotes vascular cell calcification. Arteriosclerosis, Thrombosis, and Vascular Biology 27:799-805. (doi:10.1161/01.ATV.0000258414.59393.89)
44. Jaffe IZ, Newfell BG, Aronovitz M, Mohammad NN, McGraw AP, Perreault RE, Carmeliet P, Ehsan A & Mendelsohn ME. 2010. Placental growth factor mediates aldosterone-dependent vascular injury in mice. Journal of Clinical Investigation 120:3891-3900. (doi:10.1172/JCI40205)
45. Jaffe IZ & Jaisser F. 2014. Endothelial cell mineralocorticoid receptors: turning cardiovascular risk factors into cardiovascular dysfunction. Hypertension 63:915-917. (doi:10.1161/HYPERTENSIONAHA.114.01997)
46. Jia G, Aroor AR, Martinez-Lemus LA & Sowers JR. 2014. Overnutrition, mTOR signaling, and cardiovascular diseases. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 307:R1198-R1206. (doi:10.1152/ajpregu.00262.2014)
47. Jia G, Habibi J, DeMarco VG, Martinez-Lemus LA, Whaley-Connell AT, Aroor AR, Domeier TL, Zhu Y, Meininger GA, et al. 2015. Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females. Hypertension 66:1159-1167. (doi:10.1161/HYPERTENSIONAHA.115.06015)
48. Jia G, Habibi J, Aroor AR, Martinez-Lemus LA, DeMarco VG, Ramirez-Perez FI, Sun Z, Hayden MR, Meininger GA, Mueller KB, et al. 2016. Endothelial mineralocorticoid receptor mediates diet-induced aortic stiffness in females. Circulation Research 118:935-943. (doi:10.1161/CIRCRESAHA.115.308269)
49. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E & Kawashima H. 1995. Activation of the estrogen receptor through phosphorylation by mitogenactivated protein kinase. Science 270:1491-1494. (doi:10.1126/science.270.5241.1491)
50. Kayes-Wandover KM & White PC. 2000. Steroidogenic enzyme gene expression in the human heart. Journal of Clinical Endocrinology & Metabolism 85:2519-2525. (doi:10.1210/jc.85.7.2519)
51. Koenig JB & Jaffe IZ. 2014. Direct role for smooth muscle cell mineralocorticoid receptors in vascular remodeling: novel mechanisms and clinical implications. Current Hypertension Reports 16:427. (doi:10.1007/s11906-014-0427-y)
52. Kornel L. 1981. Studies on the mechanism of mineralcorticoid-induced hypertension: evidence for the presence of an in-situ mechanism in the arterial wall for a direct action of mineralocorticoids. Clinical Biochemistry 14:282-293. (doi:10.1016/S0009-9120(81)91012-2)
53. Kornel L, Kanamarlapudi N, Travers T, Taff DJ, Patel N, Chen C, Baum RM & Raynor WJ. 1982. Studies on high affinity binding of mineralo-and glucocorticoids in rabbit aorta cytosol. Journal of Steroid Biochemistry 16:245-264. (doi:10.1016/0022-4731(82)90173-X)
54. Kornel L, Ramsay C, Kanamarlapudi N, Travers T & Packer W. 1982. Evidence for the presence in arterial walls of intracellular-molecular mechanism for action of mineralocorticoids. Clinical and Experimental Hypertension 4:1561-1582. (doi:10.3109/10641968209061625)
55. Kornel L, Kanamarlapudi N, Ramsay C & Taff DJ. 1984. Studies on arterial mineralocorticoid and glucocorticoid receptors: evidence for the translocation of steroid-cytoplasmic receptor complexes to cell nuclei. Clinical Physiology and Biochemistry 2:14-31
56. Kornel L. 1994. Colocalization of 11 beta-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. American Journal of Hypertension 7:100-103. (doi:10.1093/ajh/7.1.100)
57. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T & Marwick TH. 2011. A randomized study of the beneficial effects of aldosterone antagonism on lv function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovascular Imaging 4:1239-1249. (doi:10.1016/j.jcmg.2011.08.014)
58. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A & Marwick TH. 2013. Fibrosis and cardiac function in obesity: A randomised controlled trial of aldosterone blockade. Heart 99:320-326. (doi:10.1136/heartjnl-2012-303329)
59. Krug AW, Allenhofer L, Monticone R, Spinetti G, Gekle M, Wang M & Lakatta EG. 2010. Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-related kinase 1/2 mitogenactivated protein kinase and epidermal growth factor receptordependent pathways. Hypertension 55:1476-1483. (doi:10.1161/HYPERTENSIONAHA.109.148783)
60. Kurobe H, Hirata Y, Matsuoka Y, Sugasawa N, Higashida M, Nakayama T, Maxfield MW, Yoshida Y, Shimabukuro M, Kitagawa T, et al. 2013. Protective effects of selective mineralocorticoid receptor antagonist against aortic aneurysm progression in a novel murine model. Journal of Surgical Research 185:455-462. (doi:10.1016/j.jss.2013.05.002)
61. Kusche-Vihrog K, Sobczak K, Bangel N, Wilhelmi M, Nechyporuk-Zloy V, Schwab A, Schillers H & Oberleithner H. 2008. Aldosterone and amiloride alter ENaC abundance in vascular endothelium. Pflügers Archiv 455:849-857. (doi:10.1007/s00424-007-0341-0)
62. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A & Safar M. 2002. Increased carotid wall elastic modulus and fibronectin in aldosteronesalt-treated rats: effects of eplerenone. Circulation 106:2848-2853. (doi:10.1161/01.CIR.0000039328.33137.6C)
63. Lagrange J, Li Z, Fassot C, Bourhim M, Louis H, Nguyen Dinh Cat A, Parlakian A, Wahl D, Lacolly D, Jaisser F, et al. 2014. Endothelial mineralocorticoid receptor activation enhances endothelial protein C receptor and decreases vascular thrombosis in mice. FASEB Journal 28:2062-2072. (doi:10.1096/fj.13-238188)
64. Lattenist L, Lechner SM, Messaoudi S, Le Mercier A, El Moghrabi S, Prince S, Bobadilla NA, Kolkhof P, Jaisser F & Barrera-Chimal J. 2017. Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: Role of oxidative stress. Hypertension (doi:10.1161/HYPERTENSIONAHA.116.08526)
65. Lee RM, Dickhout JG & Sandow SL. 2016. Vascular structural and functional changes: their association with causality in hypertension: models, remodeling, and relevance. Hypertension Research (doi:10.1038/hr.2016.145)
66. Lemarié CA, Simeone SM, Nikonova A, Ebrahimian T, Deschênes ME, Coffman TM, Paradis P & Schiffrin EL. 2009. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circulation Research 105:852-859. (doi:10.1161/CIRCRESAHA.109.196576)
67. Levy DG, Rocha R & Funder JW. 2004. Distinguishing the antihypertensive and electrolyte effects of eplerenone. Journal of Clinical Endocrinology & Metabolism 89:2736-2740. (doi:10.1210/jc.2003-032149)
68. Lombès M, Oblin M, Gasc J, Baulieu EE, Farman N & Bonvalet J. 1992. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circulation Research 71:503-510. (doi:10.1161/01.RES.71.3.503)
69. Lother A, Fürst D, Bergemann S, Gilsbach R, Grahammer F, Huber TB, Hilgendorf I, Bode C, Moser M & Hein L. 2016. Deoxycorticosterone acetate/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure. Hypertension 67:130-138. (doi:10.1161/HYPERTENSIONAHA.115.06530)
70. Lumbers ER. 1999. Angiotensin and aldosterone. Regulatory Peptides 80:91-100. (doi:10.1016/S0167-0115(99)00026-9)
71. Maron BA, Zhang YY, White K, Chan SY, Handy DE, Mahoney CE, Loscalzo J & Leopold JA. 2012. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation 126:963-974. (doi:10.1161/CIRCULATIONAHA.112.094722)
72. Maron BA, Waxman AB, Opotowsky AR, Gillies H, Blair C, Aghamohammadzadeh R, Loscalzo J & Leopold JA. 2013. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). American Journal of Cardiology 112:720-725. (doi:10.1016/j. amjcard.2013.04.051)
73. Maron BA, Oldham WM, Chan SY, Vargas SO, Arons E, Zhang YY, Loscalzo J & Leopold JA. 2014. Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis. Circulation 130:168-179. (doi:10.1161/CIRCULATIONAHA.113.007690)
74. Marzolla V, Armani A, Mammi C, Moss ME, Pagliarini V, Pontecorvo L, Antelmi A, Fabbri A, Rosano G, Jaffe IZ, et al. 2017. Essential role of ICAM-1 in aldosterone-induced atherosclerosis. International Journal of Cardiology 232:233-242. (doi:10.1016/j.ijcard.2017.01.013)
75. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, et al. 2004. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 109:2792-2800. (doi:10.1161/01. CIR.0000131860.80444.AB)
76. McClain JL & Dorrance AM. 2014. Temporary mineralocorticoid receptor antagonism during the development of hypertension improves cerebral artery dilation. Experimental Biology and Medicine 239:619-627. (doi:10.1177/1535370214522586)
77. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance M, Mendelsohn ME, et al. 2012. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nature Medicine 18:1429-1433. (doi:10.1038/nm.2891)
78. McCurley A & Jaffe IZ. 2012. Mineralocorticoid receptors in vascular function and disease. Molecular and Cellular Endocrinology 350:256-265. (doi:10.1016/j.mce.2011.06.014)
79. McGraw AP, Bagley J, Chen WS, Galayda C, Nickerson H, Armani A, Caprio M, Carmeliet P & Jaffe IZ. 2013. Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. Journal of the American Heart Association 2:e000018. (doi:10.1161/jaha.112.000018)
80. McMahon GT & Dluhy RG. 2004. Glucocorticoid-remediable aldosteronism. Cardiology Review 12:44-48. (doi:10.1097/01.crd.0000096417.42861.ce)
81. Metzger D, Clifford J, Chiba H & Chambon P. 1995. Conditional sitespecific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. PNAS 92:6991-6995. (doi:10.1073/pnas.92.15.6991)
82. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME & Mourad JJ. 2005. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 45:1243-1248. (doi:10.1016/j.jacc.2005.01.015)
83. Nagase M, Ayuzawa N, Kawarazaki W, Ishizawa K, Ueda K, Yoshida S & Fujita T. 2012. Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1. Hypertension 59:500-506. (doi:10.1161/HYPERTENSIONAHA.111.185520)
84. Nagase M & Fujita T. 2013. Role of Rac1-mineralocorticoid-receptor signaling in renal and cardiac disease. Nature Reviews Nephrology 9:86-98. (doi:10.1038/nrneph.2012.282)
85. Newfell BG, Iyer LK, Mohammad NN, McGraw AP, Ehsan A, Rosano G, Huang PL, Mendelsohn ME & Jaffe IZ. 2011. Aldosterone regulates vascular gene transcription via oxidative stress-dependent and-independent pathways. Arteriosclerosis, Thrombosis, and Vascular Biology 31:1871-1880. (doi:10.1161/ATVBAHA.111.229070)
86. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, Lacolley P, Henrion D & Jaisser F. 2010. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB Journal 24:2454-2463. (doi:10.1096/fj.09-147926)
87. Noren Hooten N, Abdelmohsen K, Gorospe M, Ejiogu N, Zonderman AB & Evans MK. 2010. microRNA expression patterns reveal differential expression of target genes with age. PLoS One 5:e88942. (doi:10.1371/journal.pone.0010724)
88. Onyeagucha BC, Mercado-Pimentel ME, Hutchinson J, Flemington EK & Nelson MA. 2013. S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer. Experimental Cell Research 319:2081-2090. (doi:10.1016/j.yexcr.2013.05.009)
89. Palombo C & Kozakova M. 2016. Arterial stiffness, atherosclerosis, and cardiovascular risk: Pathophysiologic mechanisms and emerging clinical indications. Vascular Pharmacology 77:1-7. (doi:10.1016/j. vph.2015.11.083)
90. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J & Wittes J. 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine 341:709-717. (doi:10.1056/NEJM199909023411001)
91. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, et al. 2001. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone post-AMI heart failure efficacy and survival study. Cardiovascular Drugs and Therapy 15:79-87. (doi:10.1023/A:1011119003788)
92. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J & Gatlin M. 2003. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 348:1309-1321. (doi:10.1056/NEJMoa030207)
93. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, et al. 2014. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine 370:1383-1392. (doi:10.1056/NEJMoa1313731)
94. Preston IR, Sagliani KD, Warburton RR, Hill NS, Fanburg BL & Jaffe IZ. 2013. Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. American Journal of Physiology: Lung Cellular and Molecular Physiology 304:L678-L688. (doi:10.1152/ajplung.00300.2012)
95. Pruthi D, McCurley A, Aronovitz M, Galayda C, Karumanchi SA & Jaffe IZ. 2014. Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arteriosclerosis, Thrombosis, and Vascular Biology 34:355-364. (doi:10.1161/ATVBAHA.113.302854)
96. Rautureau Y, Paradis P & Schiffrin EL. 2011. Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids 76:834-839. (doi:10.1016/j.steroids.2011.02.015)
97. Rickard AJ, Morgan J, Chrissobolis S, Miller AA, Sobey CG & Young MJ. 2014. Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension 63:1033-1040. (doi:10.1161/HYPERTENSIONAHA.113.01803)
98. Rigsby CS, Pollock DM & Dorrance AM. 2007. Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. Microvascular Research 73:198-205. (doi:10.1016/j.mvr.2006.12.001)
99. Rigsby CS, Burch AE, Ogbi S, Pollock DM & Dorrance AM. 2007. Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 293:R1754-R1763. (doi:10.1152/ajpregu.00145.2007)
100. Rogerson FM & Fuller PJ. 2000. Mineralocorticoid action. Steroids 65:61-73. (doi:10.1016/S0039-128X(99)00087-2)
101. Rossier BC, Pradervand S, Schild L & Hummler E. 2002. Epithelial sodium channel and the control of sodium balance: interaction between genetic and environmental factors. Annual Review of Physiology 64:877-897. (doi:10.1146/annurev.physiol.64.082101.143243)
102. Rossier BC, Staub O & Hummler E. 2013. Genetic dissection of sodium and potassium transport along the aldosterone-sensitive distal nephron: importance in the control of blood pressure and hypertension. FEBS Letters 587:1929-1941. (doi:10.1016/j.febslet.2013.05.013)
103. Salvador AM, Nevers T, Velazquez F, Aronovitz M, Wang B, Abadia Molina A, Jaffe IZ, Karas RH, Blanton RM & Alcaide P. 2016. Intracellular adhesion molecule 1 regulates left ventricular leukocyte infiltration, cardiac remodeling, and function in pressure overload-induced heart failure. Journal of the American Heart Association 5:e003126. (doi:10.1161/JAHA.115.003126)
104. Schäfer N, Lohmann C, Winnik S, van Tits LJ, Miranda MX, Vergopoulos A, Ruschitzka F, Nussberger J, Berger S, Luscher TF, et al. 2013. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. European Heart Journal 34:3515-3524. (doi:10.1093/eurheartj/eht095)
105. Shah AM, Shah SJ, Anand IS, Sweitzer NK, O'Meara E, Heitner JF, Sopko G, Li G, Assmann SF, McKinlay SM, et al. 2014. Cardiac structure and function in heart failure with preserved ejection fraction: Baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation: Heart Failure 7:104-115. (doi:10.1161/CIRCHEARTFAILURE.113.000887)
106. Shibata S, Nagase M & Yoshida S. 2008. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nature Medicine 14:1370-1376. (doi:10.1038/nm.1879)
107. Tapia-Castillo A, Carvajal CA, Campino C, Hill C, Allende F, Vecchiola A, Carrasco C, Bancalari R, Valdivia C, Lagos C, et al. 2015. The expression of RAC1 and mineralocorticoid pathway-dependent genes are associated with different responses to salt intake. American Journal of Hypertension 28:722-728. (doi:10.1093/ajh/hpu224)
108. Tarjus A, Belozertseva E, Louis H, El Moghrabi S, Labat C, Lacolley P, Jaisser F & Galmiche G. 2015. Role of smooth muscle cell mineralocorticoid receptor in vascular tone. Pflugers Archiv 467:1643-1650. (doi:10.1007/s00424-014-1616-x)
109. Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, et al. 2008. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 118:2515-2522. (doi:10.1161/CIRCULATIONAHA.108.772665)
110. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM & Schiffrin EL. 2002. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40:504-510. (doi:10.1161/01. HYP.0000034738.79310.06)
111. Wendling O, Bornert JM, Chambon P & Metzger D. 2009. Efficient temporally-controlled targeted mutagenesis in smooth muscle cells of the adult mouse. Genesis: Journal of Genetics & Development 47:14-18. (doi:10.1002/dvg.20448)
112. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J & Weber MA. 2003. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41:1021-1026. (doi:10.1161/01. HYP.0000067463.13172.EA)
113. Xiao F, Puddefoot JR, Barker S & Vinson GP. 2004. Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension 44:340-345. (doi:10.1161/01.HYP.0000140771.21243.ed)
114. Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, et al. 2012. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. Journal of Clinical Investigation 122:2672-2679. (doi:10.1172/JCI61427)